TY - JOUR AU - Vörös, András AU - Nagy-Mikó, Bence AU - Oláh, Orsolya AU - Pankotai, Tibor AU - Újfaludi, Zsuzsanna AU - Nikolényi, Alíz AU - Lázár, György ifj AU - Ormandi, K AU - Villanyi, Zoltan TI - Cytoplasmic aggregation of RPB1 predicts failure of neoadjuvant chemotherapy against invasive carcinoma of no special type JF - VIRCHOWS ARCHIV J2 - VIRCHOWS ARCH VL - 483 PY - 2023 IS - S1 SP - S170 EP - S171 PG - 2 SN - 0945-6317 UR - https://m2.mtmt.hu/api/publication/34410430 ID - 34410430 LA - English DB - MTMT ER - TY - JOUR AU - Nagy-Mikó, Bence AU - Szatmári, Orsolya AU - Faragó-Mészáros, Réka AU - Csókási, Aliz AU - Bognár, Bence AU - Ördög, Nóra AU - Borsos, Barbara Nikolett AU - Majoros, Hajnalka AU - Újfaludi, Zsuzsanna AU - Oláh, Orsolya AU - Nikolényi, Alíz AU - Dobi, Ágnes AU - Kószó, Renáta Lilla AU - Sántha, Dóra AU - Lázár, György ifj AU - Simonka, Zsolt AU - Paszt, Attila AU - Ormándi, Katalin AU - Pankotai, Tibor AU - Boros, Imre Miklós AU - Villanyi, Zoltan AU - Vörös, András TI - Predictive Potential of RNA Polymerase B (II) Subunit 1 (RPB1) Cytoplasmic Aggregation for Neoadjuvant Chemotherapy Failure JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 24 PY - 2023 IS - 21 PG - 9 SN - 1661-6596 DO - 10.3390/ijms242115869 UR - https://m2.mtmt.hu/api/publication/34230980 ID - 34230980 AB - We aimed to investigate the contribution of co-translational protein aggregation to the chemotherapy resistance of tumor cells. Increased co-translational protein aggregation reflects altered translation regulation that may have the potential to buffer transcription under genotoxic stress. As an indicator for such an event, we followed the cytoplasmic aggregation of RPB1, the aggregation-prone largest subunit of RNA polymerase II, in biopsy samples taken from patients with invasive carcinoma of no special type. RPB1 frequently aggregates co-translationally in the absence of proper HSP90 chaperone function or in ribosome mutant cells as revealed formerly in yeast. We found that cytoplasmic foci of RPB1 occur in larger sizes in tumors that showed no regression after therapy. Based on these results, we propose that monitoring the cytoplasmic aggregation of RPB1 may be suitable for determining—from biopsy samples taken before treatment—the effectiveness of neoadjuvant chemotherapy. LA - English DB - MTMT ER - TY - JOUR AU - Tabár, László AU - Dean, Peter B. AU - Ming-Fang Yen, Amy AU - Yi-Ying Wu, Wendy AU - Tarján, Miklós AU - Lee Tucker, F. AU - Hsiu-Hsi Chen, Tony AU - Vörös, András TI - The term “classic invasive lobular carcinoma” of the breast defines breast malignancies of vastly different nature JF - EUROPEAN JOURNAL OF RADIOLOGY J2 - EUR J RADIOL VL - 168 PY - 2023 PG - 18 SN - 0720-048X DO - 10.1016/j.ejrad.2023.111119 UR - https://m2.mtmt.hu/api/publication/34181323 ID - 34181323 LA - English DB - MTMT ER - TY - JOUR AU - Almási, Szintia AU - Kuthi, Levente AU - Sejben, Anita AU - Vörös, András AU - Nagy, Ákos AU - Zombori, Tamás AU - Cserni, Gábor TI - TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin JF - VIRCHOWS ARCHIV J2 - VIRCHOWS ARCH VL - 483 PY - 2023 IS - Suppl. 1 SP - S57 EP - S57 PG - 1 SN - 0945-6317 UR - https://m2.mtmt.hu/api/publication/34172032 ID - 34172032 LA - English DB - MTMT ER - TY - JOUR AU - Tabár, László AU - Dean, Peter B. AU - Tucker, F. Lee AU - Yen, Amy Ming-Fang AU - Chen, Sam Li-Sheng AU - Lin, Abbie Ting-Yu AU - Hsu, Chen-Yang AU - Munpolsri, Pattaranan AU - Wu, Wendy Yi-Ying AU - Smith, Robert A. AU - Duffy, Stephen W. AU - Chen, Tony Hsiu-Hsi AU - Tarján, Miklós AU - Vörös, András TI - Imaging biomarkers are underutilised but highly predictive prognostic factors for the more fatal breast cancer subtypes JF - EUROPEAN JOURNAL OF RADIOLOGY J2 - EUR J RADIOL VL - 166 PY - 2023 PG - 19 SN - 0720-048X DO - 10.1016/j.ejrad.2023.111021 UR - https://m2.mtmt.hu/api/publication/34120913 ID - 34120913 N1 - Falun Central Hospital, Lasarettsvägen 10, Falun, 791 82, Sweden University of Turku, Yliopisto, Turun, FI-20014, Finland Virginia Biomedical Laboratories, Wirtz, VA, United States School of Oral Hygiene, College of Oral Medicine, Taipei Medical University, 250 Wuxing Street, Taipei, 110, Taiwan Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, 17 Hsuchow Road, Taipei, 100, Taiwan Daichung Hospital, No. 304, Guangfu Rd, Miaoli, Zhunan Township, 350, Taiwan Department of Radiation Sciences, Oncology, Umeå University, Sweden Early Cancer Detection Science, American Cancer Society, Atlanta, GA 30303, United States Centre for Prevention, Detection and Diagnosis, Wolfson Institute of Population Health, Queen Mary University of London, Charterhouse Square LondonEC1M 6BQ, United Kingdom Department of Pathology, University of Szeged, Állomás street 1, Szeged, H-6720, Hungary Export Date: 26 September 2023 CODEN: EJRAD Correspondence Address: Tabár, L.; Falun Central Hospital, Lasarettsvägen 10, Sweden; email: laszlo@mammographyed.com AB - Purpose: The development and refinement of breast imaging modalities offer a wealth of diagnostic information such as imaging biomarkers, which are primarily the mammographic appearance of the various breast cancer subtypes. These are readily available preoperatively at the time of diagnosis and can enhance the prognostic value of currently used molecular biomarkers. In this study, we investigated the relative utility of the molecular and imaging biomarkers, both jointly and independently, when predicting long-term patient outcome according to the site of tumour origin.Methods: We evaluated the association of imaging biomarkers and conventional molecular biomarkers, (ER, PR, HER-2, Ki67), separately and combined, with long-term patient outcome in all breast cancer cases having complete data on both imaging and molecular biomarkers (n = 2236) diagnosed in our Institute during the period 2008-2019. Large format histopathology technique was used to document intra- and intertumoural het-erogeneity and select the appropriate foci for evaluating molecular biomarkers.Results: The breast cancer imaging biomarkers were strongly predictive of long-term patient outcome. The mo-lecular biomarkers were predictive of outcome only for unifocal acinar adenocarcinoma of the breast (AAB), but less reliable in the multifocal AAB cases due to variability of molecular biomarkers in the individual tumour foci. In breast cancer of mesenchymal origin (BCMO), conventionally termed classic invasive lobular carcinoma, and in cancers originating from the major lactiferous ducts (ductal adenocarcinoma of the breast, DAB), the mo-lecular biomarkers misleadingly indicated favourable prognosis, whereas the imaging biomarkers in BCMO and DAB reliably indicated the high risk of breast cancer death. Among the 2236 breast cancer cases, BCMO and DAB comprised 21% of the breast cancer cases, but accounted for 45% of the breast cancer deaths.Conclusions: Integration of imaging biomarkers into the diagnostic workup of breast cancer yields a more precise, comprehensive and prognostically accurate diagnostic report. This is particularly necessary in multifocal AAB cases having intertumoural heterogeneity, in diffuse carcinomas (DAB and BCMO), and in cases with combined DAB and AAB. In such cases, the imaging biomarkers should be prioritised over molecular biomarkers in planning treatment because the latter fail to predict the severity of the disease. In combination with the use of the large section histopathology technique, imaging biomarkers help alleviate some of the current problems in breast cancer management, such as over-and under-assessment of disease extent, which carry the risk of overtreatment and undertreatment. LA - English DB - MTMT ER - TY - JOUR AU - Tabár, László AU - Bozó, Renáta AU - Dean, Peter B AU - Ormándi, Katalin AU - Puchkova, Olga AU - Oláh, Orsolya AU - Németh, István Balázs AU - Veréb, Zoltán AU - Yen, Ming-Fang AU - Chen, Li-Sheng AU - Chen, Hsiu-Hsi AU - Vörös, András TI - Does Diffusely Infiltrating Lobular Carcinoma of the Breast Arise from Epithelial-Mesenchymal Hybrid Cells? JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 24 PY - 2023 IS - 13 PG - 15 SN - 1661-6596 DO - 10.3390/ijms241310752 UR - https://m2.mtmt.hu/api/publication/34068499 ID - 34068499 AB - Classic diffusely infiltrating lobular carcinoma has imaging features divergent from the breast cancers originating from the terminal ductal lobular units and from the major lactiferous ducts. Although the term "invasive lobular carcinoma" implies a site of origin within the breast lobular epithelium, we were unable to find evidence supporting this assumption. Exceptional excess of fibrous connective tissue and the unique cell architecture combined with the aberrant features at breast imaging suggest that this breast malignancy has not originated from cells lining the breast ducts and lobules. The only remaining relevant component of the fibroglandular tissue is the mesenchyme. The cells freshly isolated and cultured from diffusely infiltrating lobular carcinoma cases contained epithelial-mesenchymal hybrid cells with both epithelial and mesenchymal properties. The radiologic and histopathologic features of the tumours and expression of the mesenchymal stem cell positive markers CD73, CD90, and CD105 all suggest development in the direction of mesenchymal transition. These hybrid cells have tumour-initiating potential and have been shown to have poor prognosis and resistance to therapy targeted for malignancies of breast epithelial origin. Our work emphasizes the need for new approaches to the diagnosis and therapy of this highly fatal breast cancer subtype. LA - English DB - MTMT ER - TY - JOUR AU - Tabár, László AU - Dean, Peter B. AU - Tucker, F. Lee AU - Yen, Amy Ming-Fang AU - Chen, Tony Hsiu-Hsi AU - Wu, Wendy Yi-Ying AU - Vörös, András TI - Multifocal and diffusely infiltrating breast cancers are highly fatal subgroups needing further improvement in diagnostic and therapeutic strategies JF - EUROPEAN JOURNAL OF RADIOLOGY J2 - EUR J RADIOL VL - 164 PY - 2023 PG - 15 SN - 0720-048X DO - 10.1016/j.ejrad.2023.110854 UR - https://m2.mtmt.hu/api/publication/33936269 ID - 33936269 N1 - Funding Agency and Grant Number: Longaberger Company's Horizon of Hope (R) campaign (Project NHPDCSGBR-GBRLONG) Funding text: The authors wish to express their thanks to Tibor Tot for the 2D large format histopathology photomicrographs. We owe a debt of gratitude to Elisabeth Klockare and Britt Marie Ericsson for their skillful preparation of all our large format, thick section histopathology specimens. The authors thank Mr. Klas Frieberg at the Medical Technical and IT Department at Falun Central Hospital for carefully collecting and providing thousands of breast images (mammograms, breast MRI, handheld and automated breast ultrasound examinations) . The authors thank Ms. Helena Hermelin, the leader of the Research Laboratory at Falun Central Hospital, for scanning the large format histopathology glasses and building a reliable catalogue for the scanned cases. This work has been supported by funding from the Longaberger Company's Horizon of Hope (R) campaign (Project NHPDCSGBR-GBRLONG) . LA - English DB - MTMT ER - TY - JOUR AU - Tabár, László AU - Dean, Peter B. AU - Lee Tucker, F. AU - Vörös, András TI - Can we improve breast cancer management using an image-guided histopathology workup supported by larger histopathology sections? JF - EUROPEAN JOURNAL OF RADIOLOGY J2 - EUR J RADIOL VL - 161 PY - 2023 PG - 11 SN - 0720-048X DO - 10.1016/j.ejrad.2023.110750 UR - https://m2.mtmt.hu/api/publication/33748939 ID - 33748939 LA - English DB - MTMT ER - TY - GEN AU - Almási, Szintia AU - Kuthi, Levente AU - Sejben, Anita AU - Vörös, András AU - Nagy, Ákos AU - Zombori, Tamás AU - Cserni, Gábor TI - TRPS1 emlőmarker expressziójának vizsgálata és értékelése cytokeratin 5 pozitív, tripla negatív emlőrákokban PY - 2023 UR - https://m2.mtmt.hu/api/publication/33733107 ID - 33733107 N1 - [előadás] AB - Célkitűzés Tripla negatív emlőrákok (TNBC) esetében az ösztrogén- és progeszteronreceptor, valamint a humán epidermális növekedési faktor receptor-2 (HER-2) expresszió hiánya figyelhető meg. A TNBCk túlnyomó része agresszív tumor, magas metasztatikus potenciállal. Jellemző rájuk az is, hogy kevésbé expresszálnak olyan markereket, melyek a metasztázisból lehetővé tennék a primer tumor, azaz az emlő eredet igazolását. Az eddig ismert emlőmarkerek, mint a gross cystic disease fluid protein-15 (GCDPF-15), a GATA binding protein 3 (GATA3), a mammaglobin (MGB) és a SRY-related HMG-box 10 (SOX10) nem kellően specifikusak emlőrákokra. A célunk a trichorhinophalangeal syndrome type 1 (TRPS1), mint lehetséges emlőmarker vizsgálata tripla negatív, cytokeratin 5 pozitív (CK5+) emlőrákokban, valamint a TRPS1 expresszió értékelésének reprodukálhatósága volt. Módszer Százhúsz tripla negatív emlőrákból készült tissue microarray (TMA) blokkok TRPS1 immunhisztokémiai festődését vizsgálatuk. A pozitivitás küszöbértéke legalább 10%-os nukleáris festődés volt, ennek reprodukálhatóságát is vizsgáltuk kappa statisztikával. A minták GATA3, GCDFP-15, MGB és SOX10 pozitivitására vonatkozó adatokat korábbi vizsgálatainkból nyertük. Eredmények Száztizenhét minta lett értékelhető. TRPS1 pozitivitás 92 (79%) esetben volt, ami felülmúlja a korábban tesztelt markereket, melyekben a következőképpen alakult a pozitivitás: SOX10: 82 (70%), GATA3: 11 (9%), MGB: 10 (9%) és GCDFP-15: 7 (6%). A 25 TRPS1 negatív esetből 11 pozitívnak bizonyult SOX10 immunhisztokémiával. A TRPS1, illetve SOX10 kettős negatív esetekből 5 bizonyult pozitívnak egyéb markerekkel. A reprodukálhatóság tekintetében a TRPS1 expresszió esetében jelentős véleményegyezést tapasztaltunk (Cohen kappa: 0,67). Megbeszélés Az 5 vizsgált markerből a TRPS1 bizonyult legszenzitívebb emlő eredetet igazoló markernek, a CK5+ TNBCk kapcsán. A TRPS1 negatív esetek túlnyomó része SOX10 pozitivitást mutatott, a fennmaradó dupla negatív esetek egy része viszont pozitívnak bizonyult GCDFP15 és/vagy MGB markerekkel. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Almási, Szintia AU - Kuthi, Levente AU - Sejben, Anita AU - Vörös, András AU - Nagy, Ákos AU - Zombori, Tamás AU - Cserni, Gábor TI - TRPS1 expression in cytokeratin 5 expressing triple negative breast cancers, its value as a marker of breast origin JF - VIRCHOWS ARCHIV J2 - VIRCHOWS ARCH VL - 482 PY - 2023 IS - 5 SP - 861 EP - 868 PG - 8 SN - 0945-6317 DO - 10.1007/s00428-023-03535-4 UR - https://m2.mtmt.hu/api/publication/33731548 ID - 33731548 N1 - Funding Agency and Grant Number: University of Szeged; Open Access Fund [6142]; University of Szeged, Faculty of Medicine Research Fund-Hetenyi Geza Grant [5S 340 A202] Funding text: Open access funding provided by University of Szeged, (Open Access Fund, Grant No. 6142). This research was funded by the University of Szeged, Faculty of Medicine Research Fund-Hetenyi Geza Grant (Grant No. 5S 340 A202) AB - The lack of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 expression in breast cancer (BC) is the basis for the categorization of the tumour as triple negative breast carcinoma (TNBC). The majority of TNBCs are aggressive tumours with common metastases and decreased expression of markers that could help in identifying the metastatic lesion as of mammary origin. Breast markers, such as gross cystic disease fluid protein-15 (GCDPF-15), GATA binding protein 3 (GATA3), mammaglobin (MGB) and SOX10, are not uniquely specific to BC. Our aim was to evaluate trichorhinophalangeal syndrome type 1 (TRPS1) protein as a breast marker in a series of cytokeratin-5-expressing TNBC, mostly corresponding to basal-like TNBCs, previously characterized for the expression of other breast markers. One hundred seventeen TNBCs in tissue microarrays were immunostained for TRPS1. The cut-off for positivity was ≥ 10%. The reproducibility of this classification was also assessed. TRPS1 positivity was detected in 92/117 (79%) cases, and this exceeded the expression of previously tested markers like SOX10 82 (70%), GATA3 11 (9%), MGB 10 (9%) and GCDFP-15 7 (6%). Of the 25 TRPS1-negative cases, 11 were positive with SOX10, whereas 5 to 6 dual negatives displayed positivity for the other makers. The evaluation showed substantial agreement. Of the five markers compared, TRPS1 seems the most sensitive marker for the mammary origin of CK5-expressing TNBCs. Cases that are negative are most often labelled with SOX10, and the remainder may still demonstrate positivity for any of the 3 other markers. TRPS1 has a place in breast marker panels. LA - English DB - MTMT ER -